Carteolol
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Carteolol
- Carteolol: From Beta-Blocker Use (Original Indication Not Recorded) to Primary Hereditary Glaucoma
Carteolol: From Beta-Blocker Use (Original Indication Not Recorded) to Primary Hereditary Glaucoma
One-Sentence Summary
Carteolol is a non-selective beta-blocker marketed in the US as a solution. The record does not list its original indication. The TxGNN model predicts it may be effective for primary hereditary glaucoma, but the only support is the model score, with 0 clinical trials and 0 publications supplied.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the record (the approved indication text is empty) |
| Predicted New Indication | Primary hereditary glaucoma |
| TxGNN Prediction Score | 99.92% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 1 (ANDA075476) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the record. Carteolol is a non-selective beta-adrenergic blocker. Beta-blockers lower intraocular pressure by reducing aqueous humor production, so a link to glaucoma is biologically plausible.
Carteolol is already marketed as an ophthalmic agent for glaucoma and ocular hypertension in many jurisdictions. This record’s empty original-indication field is therefore probably a gap in the data, not proof that this is a true repurposing case. The model score alone cannot separate a genuine repurposing signal from a use the label already covers.
It is also unresolved whether “primary hereditary glaucoma” (for example congenital or juvenile forms) differs from the adult open-angle indication on the label. Beta-blocker use in infants carries systemic safety concerns, which makes this distinction important.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ANDA075476 | Carteolol Hydrochloride (Sandoz Inc) | Solution | Not stated in record |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a very high TxGNN score, with no trials or literature. The record also lacks the original indication, mechanism data, and label safety information. A known label use cannot yet be ruled out.
To proceed, the following is needed:
- Label indications and package insert warnings and contraindications, confirmed from FDA sources
- Mechanism of action data confirmed in DrugBank
- A literature and trial search for pediatric or hereditary glaucoma studies
- A review of systemic safety for beta-blocker use in infants and children
- A check of whether the route of administration matches the intended use (the record lists the route only as “Other”)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.